Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ALPELISIB for Pik3ca-activated mutation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 150 adverse event reports in the FDA FAERS database where ALPELISIB was used for Pik3ca-activated mutation.

Most Reported Side Effects for ALPELISIB

Side Effect Reports % Deaths Hosp.
Hyperglycaemia 1,575 18.7% 94 415
Rash 1,393 16.6% 43 234
Diarrhoea 1,336 15.9% 55 267
Blood glucose increased 1,105 13.1% 38 261
Death 921 10.9% 919 63
Nausea 860 10.2% 38 177
Fatigue 817 9.7% 33 136
Decreased appetite 546 6.5% 28 102
Weight decreased 508 6.0% 22 92
Malignant neoplasm progression 497 5.9% 136 99
Vomiting 479 5.7% 35 164
Asthenia 344 4.1% 34 110
Stomatitis 343 4.1% 9 55
Drug ineffective 324 3.9% 43 43
Pyrexia 272 3.2% 13 118

Other Indications for ALPELISIB

Product used for unknown indication (3,166) Breast cancer (1,914) Breast cancer metastatic (1,372) Breast cancer female (476) Pik3ca related overgrowth spectrum (229) Hormone receptor positive her2 negative breast cancer (171) Neoplasm malignant (102) Ovarian cancer (54) Metastases to bone (43) Breast cancer stage iv (40)

Other Drugs Used for Pik3ca-activated mutation

FULVESTRANT (36) CAPIVASERTIB (6) EVEROLIMUS (6) RIBOCICLIB (6) CYCLOPHOSPHAMIDE (5) EPIRUBICIN (5) EXEMESTANE (5) PALBOCICLIB (5) TAMOXIFEN (5)

Related Pages

ALPELISIB Full Profile All Pik3ca-activated mutation Drugs ALPELISIB Demographics ALPELISIB Timeline